Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-mesothelin/MMAE antibody-drug conjugate RC88

An antibody-drug conjugate (ADC) composed of an antibody directed against the human cell surface glycoprotein mesothelin and conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-mesothelin/MMAE ADC RC88 targets and binds to the tumor associated antigen (TAA) mesothelin on the surface of tumor cells. Upon internalization and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in mesothelin-expressing tumor cells. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-mesothelin/MMAE ADC RC88
Code name:ADC RC88
RC 88
RC-88
RC88
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search